Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

Charlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, Diane Picton, Mark Wilson, Katrina Gatley, Anita Chhabra, M Loredana Marcovecchio, A Emile J Hendriks, Hilde Morobé, Piotr Jaroslaw Chmura, Simon Bond, Bärbel Aschemeier-Fuchs, Mikael Knip, Timothy Tree, Lut Overbergh, Jaivier Pall, Olivier Arnaud, Michael J Haller, Almut Nitsche, Anke M Schulte, Chantal Mathieu, Adrian Mander, David Dunger

Open source

DOI: 10.1136/bmjopen-2021-053669
Published: 2021-12
Container: BMJ Open
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2021-053669,
  title = {Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes},
  author = {Charlotte S Wilhelm-Benartzi and Sarah E Miller and Sylvaine Bruggraber and Diane Picton and Mark Wilson and Katrina Gatley and Anita Chhabra and M Loredana Marcovecchio and A Emile J Hendriks and Hilde Morobé and Piotr Jaroslaw Chmura and Simon Bond and Bärbel Aschemeier-Fuchs and Mikael Knip and Timothy Tree and Lut Overbergh and Jaivier Pall and Olivier Arnaud and Michael J Haller and Almut Nitsche and Anke M Schulte and Chantal Mathieu and Adrian Mander and David Dunger},
  year = {2021},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2021-053669},
  url = {https://doi.org/10.1136/bmjopen-2021-053669}
}

RIS

TY  - JOUR
TI  - Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes
AU  - Charlotte S Wilhelm-Benartzi
AU  - Sarah E Miller
AU  - Sylvaine Bruggraber
AU  - Diane Picton
AU  - Mark Wilson
AU  - Katrina Gatley
AU  - Anita Chhabra
AU  - M Loredana Marcovecchio
AU  - A Emile J Hendriks
AU  - Hilde Morobé
AU  - Piotr Jaroslaw Chmura
AU  - Simon Bond
AU  - Bärbel Aschemeier-Fuchs
AU  - Mikael Knip
AU  - Timothy Tree
AU  - Lut Overbergh
AU  - Jaivier Pall
AU  - Olivier Arnaud
AU  - Michael J Haller
AU  - Almut Nitsche
AU  - Anke M Schulte
AU  - Chantal Mathieu
AU  - Adrian Mander
AU  - David Dunger
PY  - 2021
JO  - BMJ Open
DO  - 10.1136/bmjopen-2021-053669
UR  - https://doi.org/10.1136/bmjopen-2021-053669
ER  -

APA

Wilhelm-Benartzi, C. S., Miller, S. E., Bruggraber, S., Picton, D., Wilson, M., Gatley, K., Chhabra, A., Marcovecchio, M. L., Hendriks, A. E. J., Morobé, H., Chmura, P. J., Bond, S., Aschemeier-Fuchs, B., Knip, M., Tree, T., Overbergh, L., Pall, J., Arnaud, O., Haller, M. J., Nitsche, A., Schulte, A. M., Mathieu, C., Mander, A., & Dunger, D. (2021). Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open. https://doi.org/10.1136/bmjopen-2021-053669

Source records

crossref · retrieved 2026-09-26T13:53:25.161Z